Norges Bank Adverum Biotechnologies, Inc. Transaction History

Norges Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$9.26 - $14.36 $592,528 - $918,867	-63,988 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$9.84 - $14.26 $629,641 - $912,468	63,988 New	63,988 $694,000
Q4 2020 Feb 10, 2021	SELL	$9.84 - $14.26 $2.18 Million - $3.16 Million	-221,789 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$10.3 - $21.64 $2.28 Million - $4.8 Million	221,789 New	221,789 $2.28 Million
Q1 2020 May 08, 2020	SELL	$7.98 - $16.32 $1.4 Million - $2.85 Million	-174,867 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$5.12 - $12.22 $895,319 - $2.14 Million	174,867 New	174,867 $2.01 Million
Q4 2019 Feb 12, 2020	SELL	$5.12 - $12.22 $1.26 Million - $3 Million	-245,861 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$5.24 - $15.89 $1.29 Million - $3.91 Million	245,861 New	245,861 $1.34 Million
Q3 2019 Nov 08, 2019	SELL	$5.24 - $15.89 $518,807 - $1.57 Million	-99,009 Closed	0 $0
Q2 2019 Aug 13, 2020	SELL	$5.1 - $11.89 $348,146 - $811,658	-68,264 Reduced 40.81%	99,009 $1.18 Million
Q3 2016 Nov 13, 2017	BUY	N/A	167,273	167,273 $0

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.